Cebu Pacific Enhances Payment Method Features with CellPoint Digital’s Payment Orchestration Platform
10.11.2021 16:21:00 EET | Business Wire | Press release
CellPoint Digital, a fintech leader in payment orchestration, today announces the next leg of its partnership with Cebu Pacific, the largest airline in the Philippines.
Cebu Pacific is one of the most successful low-cost airlines in the world, having flown over 22 million passengers to over 60 destinations in 2019, with 70% of these bookings being made directly via the carrier’s digital channels.
Following the successful implementation of CellPoint Digital’s cutting-edge Payment Orchestration Platform, Velocity, across all of Cebu Pacific’s digital channels last year, the airline has now implemented new alternative payment methods to provide more flexible options to their customer’s payment experience. Thanks to the PSP/acquirer agnostic Velocity platform, Cebu Pacific customers will now have access to the following popular payment methods: GCash, GrabPay and PayMaya.
The new alternative payment methods boast wide-ranging end-user benefits, including enabling split payments between travel fund vouchers and cash, and converting local currencies in real-time. For the airline itself, providing more payment methods should increase revenues, and by optimising card payment processing across multiple acquirers, they will be able to do real-time transaction monitoring – by market, and by payment method – all delivered conveniently in one place.
The intelligent routing module already dynamically optimises the routing of each transaction made via a bespoke network of acquiring banks, thereby maximising acceptance rates and lowering transaction costs.
Candice Iyog, Vice-president for Marketing and Customer Experience at Cebu Pacific added: “Our partnership with CellPoint Digital continues to go from strength to strength. As the world begins to open back up and consumers are more used to using flexible digital payment methods than ever before, we’re proud to be able to offer our customers a frictionless customer experience at checkout by giving them the payment methods they most want to use.”
Commenting on the announcement Kristian Gjerding, CEO of CellPoint Digital commented: “We’re delighted to announce this evolution in our partnership with Cebu Pacific. Airlines have, by necessity, some of the most complex payment ecosystems of modern merchants, and an equally diverse customer base to match. By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we have simplified the payment process for Cebu while bolstering its offering with popular alternative payment methods for its customers.”
The news comes as the APAC airline sector gears up to take off again following the disruption caused by the COVID-19 pandemic, with 77% of APAC airline customers ready to travel as soon as restrictions fully ease. Via its access to CellPoint Digital’s growing ecosystem, Cebu Pacific is ready to maximise the payments journey for APAC travellers with payment methods covering over 40 local and global cards, and over 350 alternative payment methods.
The future is promising for the partnership as the two companies work towards introducing more new features such as stored cards and other popular APMs, while also empowering Cebu’s B2B offering with more payment capabilities.
To find out more about CellPoint Digital, visit: https://cellpointdigital.com/
To find out more about Cebu Pacific, visit: https://www.cebupacificair.com/
ENDS
About CellPoint Digital
CellPoint Digital makes payments easier™ for airlines, travel companies and other international merchants and their customers.
CellPoint Digital is a fintech leader in payment orchestration. Our main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment eco-system across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rate and minimise payment costs. CellPoint Digital also provides an end-to-end digital commerce platform to airlines that masters the entire customer sales cycle and maximises the conversion rate.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About Cebu Pacific
Cebu Pacific Air is one of the most successful low-cost carriers in the world and a pioneer of the “low fare, great value” strategy. Cebu started operations in 1996 and has since carried over 150 million passengers. Cebu is the largest carrier in the Philippine air transportation industry, offering low-cost services to more destinations and routes with higher flight frequency within the Philippines than any other airline. It began long-haul services in 2013. Cebu currently offers flights to 37 Philippine and 26 international destinations, spanning Asia, Australia, and the Middle East. Cebu offers a uniquely upbeat flying experience, offering fun in the skies with our “Fun Games” on board. Visit https://cebupacificaircorporate.com/Pages/company-info.aspx to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005810/en/
Contact information
Becky Sales
becky@skyparlour.com
07803204780
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom